Research programme: small molecule cancer therapeutics - FORMA Therapeutics/NanosynAlternative Names: Epigenetics cancer therapeutics; Protein homeostatis cancer therapeutics
Latest Information Update: 31 Jul 2014
At a glance
- Originator FORMA Therapeutics; Nanosyn
- Class Small molecules
- Mechanism of Action Deubiquitinating enzyme modulators; Histone acetyltransferase modulators; Histone deacetylase modulators; Histone demethylase modulators; Histone methyltransferase modulators; Protein modulators; Ubiquitin protein ligase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Jul 2014 Early research in Cancer in USA (unspecified route)